Nonalcoholic fatty liver disease (NAFLD) Archives - CDR

Noninvasive technologies help battle diabetes and NAFLD

March 18, 2019 by Dr. Juan Frias American Liver Foundation, diabetes, Nonalcoholic fatty liver disease (NAFLD) March 18, 2019, Pharmacy

The American Liver Foundation estimates that over 30% of the U.S. population has some degree of nonalcoholic fatty liver disease (NAFLD), the most common type of liver disease in the Western world. This can impact other facets of their overall health, because NAFLD has been linked to diabetes, obesity, insulin resistance and other metabolic risk

Diabetes increases risk for liver disease

December 11, 2018 by Laurent Sandrin Echosens, FibroScan technology, Laurent Sandrin, Nonalcoholic fatty liver disease (NAFLD) Issue 12-10-2018, Pharmacy

Nonalcoholic fatty liver disease (NAFLD) is an asymptomatic disease that affects about 100 million Americans. Being overweight, obese or diabetic are primary risk factors for NAFLD, an umbrella term describing those liver diseases that aren’t related to alcohol consumption. Whereas consumption of too much alcohol over a period of several years is known to damage